MaxCyte (MXCT) is a US-listed Healthcare company in Biotechnology with a market capitalization of
25M, trading at
.17 on the NASDAQ. This SniperIQ fundamentals page covers MaxCyte's valuation, profitability (net margin -121.2%), revenue (
3M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
25M
Net Margin-121.2%
Revenue (FY25)
3M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is MaxCyte's market cap?
MaxCyte (MXCT) has a market capitalization of approximately
25M, trading at
.17 on the NASDAQ. Market cap moves with the live share price.
What is MaxCyte's P/E ratio?
MaxCyte's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MaxCyte?
MaxCyte runs a net profit margin of -121.2%, a gross margin of 80.7%, and an operating margin of -119.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MaxCyte generate?
MaxCyte reported revenue of
3M for fiscal year 2025, with net income of -$45M and earnings per share (EPS) of -0.42. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MaxCyte pay a dividend?
MaxCyte does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MaxCyte financially healthy?
MaxCyte carries a debt-to-equity ratio of 0.10x and a current ratio of 12.04x, with a market beta of 1.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MaxCyte a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MaxCyte (MXCT) the key facts are: market cap
25M, revenue
3M, 52-week range 0.643-2.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MaxCyte's full fundamentals live
Get MaxCyte's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.